How Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Can Impact Your Portfolio Volatility

Anyone researching Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The other type, which cannot be diversified away, is the volatility of the entire market. Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market.

Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). However, Warren Buffett said ‘volatility is far from synonymous with risk’ in his 2014 letter to investors. So, while useful, beta is not the only metric to consider. To use beta as an investor, you must first understand that the overall market has a beta of one. A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

See our latest analysis for Beijing Tong Ren Tang Chinese Medicine

What 3613’s beta value tells investors

As it happens, Beijing Tong Ren Tang Chinese Medicine has a five year beta of 0.97. This is fairly close to 1, so the stock has historically shown a somewhat similar level of volatility as the market. While history does not always repeat, this may indicate that the stock price will continue to be exposed to market risk, albeit not overly so. Many would argue that beta is useful in position sizing, but fundamental metrics such as revenue and earnings are more important overall. You can see Beijing Tong Ren Tang Chinese Medicine’s revenue and earnings in the image below.

SEHK:3613 Income Statement Export December 26th 18
SEHK:3613 Income Statement Export December 26th 18

Could 3613’s size cause it to be more volatile?

Beijing Tong Ren Tang Chinese Medicine is a small company, but not tiny and little known. It has a market capitalisation of HK$11b, which means it would be on the radar of intstitutional investors. Small companies often have a high beta value because the stock price can move on relatively low capital flows. So it’s interesting to note that this stock historically has a beta value quite close to one.

What this means for you:

Since Beijing Tong Ren Tang Chinese Medicine has a beta close to one, it will probably show a positive return when the market is moving up, based on history. If you’re trying to generate better returns than the market, it would be worth thinking about other metrics such as cashflows, dividends and revenue growth might be a more useful guide to the future. This article aims to educate investors about beta values, but it’s well worth looking at important company-specific fundamentals such as Beijing Tong Ren Tang Chinese Medicine’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Future Outlook: What are well-informed industry analysts predicting for 3613’s future growth? Take a look at our free research report of analyst consensus for 3613’s outlook.
  2. Past Track Record: Has 3613 been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of 3613’s historicals for more clarity.
  3. Other Interesting Stocks: It’s worth checking to see how 3613 measures up against other companies on valuation. You could start with this free list of prospective options.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.